PMID- 30402741
OWN - NLM
STAT- MEDLINE
DCOM- 20190228
LR  - 20221207
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 145
IP  - 2
DP  - 2019 Feb
TI  - The role of EP3-receptor expression in cervical dysplasia.
PG  - 313-319
LID - 10.1007/s00432-018-2785-3 [doi]
AB  - PURPOSE: Prostaglandin-mediated inflammatory reactions play a major role in 
      different cancers. Prostaglandin E2-receptor 3 (EP3) expression correlates with 
      FIGO stages in cervical cancer and has been shown to be an independent prognostic 
      factor for overall survival. EP3 expression levels in cervical intraepithelial 
      neoplasia (CIN) as the precursor lesion of cervical cancer are currently unknown. 
      METHODS: EP3 expression was analyzed by immunohistochemistry in 124 patient 
      samples (CIN 1-3 and healthy controls) using the IR-scoring system. Expression 
      levels were correlated with clinical outcome to assess for prognostic relevance 
      in patients with CIN 2. Data analysis was performed using Kruskal-Wallis and 
      Mann-Whitney U test. RESULTS: EP3 expression levels significantly correlated with 
      different grades of cervical dysplasia. Median EP3-IRS in healthy cervical tissue 
      was 12 (n = 13) compared to 9 in CIN 1 (n = 38; p = 0.031 vs. healthy control), 6 
      in CIN 2 (n = 45; p < 0.001 vs. CIN 1) and 4 in CIN 3 (n = 28, p = 0.008 vs. CIN 
      2). The percentage of EP3 expressing cells in CIN 2 lesions was significantly 
      lower in progressive than in regressive cases (mean percentage of EP3 positive 
      cells in progress: 3.8%, n = 18; in regress: 9.3%, n = 20; p = 0.040). 
      CONCLUSION: EP3 expression significantly decreases with higher grades of cervical 
      intraepithelial neoplasia-which is in line with published IR scores in cervical 
      cancer patients-and seems to be a prognostic marker for regression or progression 
      of CIN 2 lesions. Our findings support the importance of the prostanoid pathway 
      in cervical cancer and could help to identify targets for future therapies.
FAU - Hester, Anna
AU  - Hester A
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Ritzer, Manuel
AU  - Ritzer M
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Kuhn, Christina
AU  - Kuhn C
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Schmoeckel, Elisa
AU  - Schmoeckel E
AD  - Department of Pathology, LMU Munich, Thalkirchnerstrasse 36, 80337, Munich, 
      Germany.
FAU - Mayr, Doris
AU  - Mayr D
AD  - Department of Pathology, LMU Munich, Thalkirchnerstrasse 36, 80337, Munich, 
      Germany.
FAU - Kolben, Thomas
AU  - Kolben T
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Dannecker, Christian
AU  - Dannecker C
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Mahner, Sven
AU  - Mahner S
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Jeschke, Udo
AU  - Jeschke U
AUID- ORCID: 0000-0003-2623-3235
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany. udo.jeschke@med.uni-muenchen.de.
FAU - Kolben, Theresa Maria
AU  - Kolben TM
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20181107
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (PTGER3 protein, human)
RN  - 0 (Receptors, Prostaglandin E, EP3 Subtype)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Case-Control Studies
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Prognosis
MH  - Receptors, Prostaglandin E, EP3 Subtype/*metabolism
MH  - Uterine Cervical Neoplasms/*metabolism/pathology
MH  - Uterine Cervical Dysplasia/*metabolism/pathology
OTO - NOTNLM
OT  - CIN
OT  - Cervical cancer
OT  - Cervical intraepithelial neoplasia
OT  - EP-receptor
OT  - EP3
OT  - Prostaglandin E2
EDAT- 2018/11/08 06:00
MHDA- 2019/03/01 06:00
CRDT- 2018/11/08 06:00
PHST- 2018/10/09 00:00 [received]
PHST- 2018/10/27 00:00 [accepted]
PHST- 2018/11/08 06:00 [pubmed]
PHST- 2019/03/01 06:00 [medline]
PHST- 2018/11/08 06:00 [entrez]
AID - 10.1007/s00432-018-2785-3 [pii]
AID - 10.1007/s00432-018-2785-3 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2019 Feb;145(2):313-319. doi: 10.1007/s00432-018-2785-3. 
      Epub 2018 Nov 7.